Krystal Biotech (NASDAQ:KRYS – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Krystal Biotech to similar companies based on the strength of its dividends, analyst recommendations, risk, profitability, institutional ownership, earnings and valuation.
Profitability
This table compares Krystal Biotech and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Krystal Biotech Competitors | -9,054.47% | -198.89% | -30.64% |
Volatility & Risk
Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Krystal Biotech’s peers have a beta of 1.12, indicating that their average share price is 12% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Krystal Biotech and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 1 | 1 | 10 | 2 | 2.93 |
| Krystal Biotech Competitors | 9782 | 15052 | 45296 | 1571 | 2.54 |
Krystal Biotech currently has a consensus target price of $375.00, indicating a potential upside of 22.94%. As a group, “Biotechnology” companies have a potential upside of 99.31%. Given Krystal Biotech’s peers higher probable upside, analysts clearly believe Krystal Biotech has less favorable growth aspects than its peers.
Institutional & Insider Ownership
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Krystal Biotech and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Krystal Biotech | $389.13 million | $204.83 million | 38.22 |
| Krystal Biotech Competitors | $743.53 million | $13.62 million | -10.02 |
Krystal Biotech’s peers have higher revenue, but lower earnings than Krystal Biotech. Krystal Biotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Krystal Biotech beats its peers on 10 of the 13 factors compared.
Krystal Biotech Company Profile
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
